US 12,246,031 B2
Compositions and methods for tumor immunotherapy
Arthur Krieg, Cambridge, MA (US); Aaron Morris, Brighton, MA (US); David Mauro, Washington Crossing, PA (US); George Weiner, Iowa City, IA (US); and Mohammed Milhem, Iowa City, IA (US)
Assigned to CHECKMATE PHARMACEUTICALS, INC., Cambridge, MA (US)
Appl. No. 16/969,076
Filed by CHECKMATE PHARMACEUTICALS, INC., Cambridge, MA (US)
PCT Filed Feb. 12, 2019, PCT No. PCT/US2019/017680
§ 371(c)(1), (2) Date Aug. 11, 2020,
PCT Pub. No. WO2019/160866, PCT Pub. Date Aug. 22, 2019.
Claims priority of provisional application 62/630,022, filed on Feb. 13, 2018.
Prior Publication US 2021/0030783 A1, Feb. 4, 2021
Int. Cl. A61K 31/7125 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/7125 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method of treating lymphoma in a subject, said method comprising administering to the subject at least one dose of a composition comprising a toll-like receptor 9 (TLR9) agonist,
wherein the TLR9 agonist comprises an A-class CpG DNA comprising the sequence of SEQ ID NO: 82;
wherein the TLR9 agonist is formulated as a virus-like particle (VLP);
wherein the composition comprising the TLR9 agonist is administered by intratumoral or peritumoral injection;
wherein the composition comprising the TLR9 agonist is administered at a dose of about 1 mg to about 100 mg per administration; and
wherein the composition comprising the TLR9 agonist is administered in a volume of 5 mL.